The recently passed “One Big Beautiful Bill” in the U.S. House of Representatives is a complex combination of various ideas and policies in one large, overarching bill. While not an international health policy document per se, its impact on the U.S. healthcare system, a major global health player, is worth examining.
At its core, the bill changes existing U.S. health programs, particularly Medicaid and the Affordable Care Act (ACA) marketplaces. Non-partisan projections show millions more uninsured Americans. This is due to stricter eligibility requirements, new administrative burdens and reduced financial assistance for health insurance premiums. For example, new work requirements for Medicaid recipients and more frequent eligibility checks could kick millions off, including seniors and people with disabilities. Changes to ACA premium tax credits, like annual re-verification and eliminating provisional eligibility, will make coverage less accessible and more expensive for many.
The domestic consequences of all this could have international ripples. A less healthy U.S. population, with higher out-of-pocket costs and reduced access to care, could see public health metrics decline. This could mean public health resources are redirected domestically rather than internationally. For example, if chronic disease prevalence increases due to reduced access to preventive care, resources that might go to global health security or humanitarian aid could be used to address internal health crises.
Furthermore, changes to U.S. healthcare financing, including potential shifts in federal funding to state Medicaid programs, could impact state budgets. This could indirectly affect their ability to participate in or support international health collaborations since state budgets fund various partnerships and programs. The bill also includes provisions on Pharmacy Benefit Managers and physician fee schedules which affect domestic drug costs and provider reimbursements. But in a global pharmaceutical market, changes in U.S. drug pricing and market dynamics could, in the long term, influence research and development priorities, drug availability and pricing strategies globally, though this would be indirect and diffuse. Though the “One Big Beautiful Bill” is a domestic document, its impact on the U.S. health and economy has international implications. How much of that translates into actual international policy will depend on a lot of variables: how the bill is implemented, how others react, and U.S. foreign policy priorities.
IMAGE CREDIT: NPR
Leave a Reply